IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Chile
The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... |
Pharmaceutical Key Trends 2011
Biosimilar Market Overview
In 2009, the combined biosimilars market size for the US and five
major European markets was $150m. With more than 30 branded biologics
with sales of $51bn set to lose... |
Pricing and Reimbursement: Innovative Risk-Sharing Strategies
Introduction
Novel niche biologics entering the market require high price points in order to provide manufacturers with a return on investment. However, with heightening regulatory scrutiny and increasing cost-pressures, a balance... |
A Guide to Drug Pricing and Reimbursement
Drug pricing is one of the key levers that determine the profitability of a drug company. Premium pricing of a new drug helps cover the high cost of innovation and... |
Pricing and Reimbursement in the US
Innovation and robust pharmacoeconomic analysis are ke
Introduction
The US is the leading global drugs market in terms of sales and profit margin. However, drug companies are facing an unprecedented number of challenges in maintaining revenue growth: fewer... |
IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Ireland
The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... |
The Impact of US Healthcare Reform on Pharma
This report carries out a detailed analysis of the provisions of healthcare reform and their effects on the pharmaceutical industry. Strategies for optimizing promotional activities and pipelines for the future... |
Pricing & Reimbursement in Europe
Can the drive for cost effectiveness overcome cost containment?
Introduction
Combined drug sales in the five major European markets represent the second-biggest market globally after the US. Unlike the US, which is dominated by a wide range of private payers,... |
Impact of Pharmacogenomics on Public Healthcare Policy
Educating Patients, Payors and Healthcare Providers
Immense advances in genetic code decipherment over the last decade have recently led to personalized medicine, or 'the right drug for the right person', becoming an achievable concept. Pharmacogenomics (PGx)... |
Emerging Markets Series: Indonesia and Philippines
Opportunities for multinational pharmaceutical players
Introduction
As the developed markets are becoming increasingly mature, Pharma is turning to the emerging markets, where long-term growth can be sustained. Of particular interest are Indonesia and the Philippines, which... |
Orthopedics Markets
Orthopedics is a medical specialty that deals with the diagnosis and treatment of disorders and injuries to the skeletal system and the muscles, joints and ligaments associated with it. The... |
Wound Treatments in Belgium
Euromonitor International's Wound Treatments in Belgium report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales... |
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006
Despite their diversity, global healthcare systems are increasingly converging in the need and desire to contain costs of healthcare, and especially those associated with pharmaceuticals. At the same time,... |
China Pharmaceutical Market Overview
The Chinese hospital prescription pharma market generated sales of $22.9 billion in 2009, with an annual growth rate of 26.5% between 2008 and 2009. Key growth drivers include China's support... |
Global Generics Guide: Part 2
Benchmarking country markets and strategic issue
Introduction
The generics market is undergoing significant change, with intense merger and acquisition activity, a raft of upcoming patent expiries and new legislation being enacted to promote generic prescription in the... |
Slimming Products in Brazil
Euromonitor International's Slimming Products in Brazil report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data... |
US Pharmaceutical Market Overview
Healthcare reform, economic pressures and the patent cliff set to impact Pharma
Introduction
The US prescription pharmaceutical market was valued at $279 billion in 2009, with an annual growth rate of 5.5% between 2008 and 2009, having grown at a compound annual growth... |
Pharmaceutical Pricing Compendium
A practical guide to the pricing and reimbursement of medicines
Pricing and reimbursement is one of the most complicated and important business issues that the pharmaceuticals industry has to deal with.
Setting the right price and ensuring that the product is... |
Israel Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
Israel Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
Summary
This report is an essential source for in-depth information and data relating to the Israel drug delivery devices market. It... |
Pricing and Reimbursement Strategies for Diagnostics
Overcoming reimbursement issues and navigating the regulatory environment
The reimbursement for diagnostics is the key requirement for both the diagnostic providers and the payers because while 5-7% of the hospital cost is incurred on diagnostics, they are used... |
Pricing and Reimbursement in Key Asia Pacific Markets
IntroductionWith the Asia-Pacific markets growing rapidly, they are becoming increasingly attractive for Pharma to enter. However, a number of key P&R developments and reforms are set to change the healthcare... |
